ClinicalTrials.gg
CompletedNCT02974855Updated Dec 4, 2019Results posted

PF-06741086 Multiple Dose Study in Severe Hemophilia

A Phase 2 interventional study of PF-06741086 and PF-06741086 in Hemophilia A or B, sponsored by Pfizer. Completed at 10 sites in 6 countries. Open to male participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2019-12-04.

Sponsored by Pfizer · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
27
Allocation
Non-randomized
Ages
18 Years to 64 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 47 studies in Hemophilia A by Pfizer — 6 open to participants now, 9 under way, 6 of them phase 3. Hemophilia A · Pfizer.

Enrollment
18th of 32
27 · median 34
Started
2017
with 4 others
Phase 2
4 of 47
none open now
Registered
27th of 47
by date

Among the 47 studies in Hemophilia A by Pfizer, this one is the 18th largest by enrollment of the 32 interventional ones that give a count, is one of 5 that started in 2017, is one of 4 in phase 2, and was the 27th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

6 of the 47 studies in Hemophilia A by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 64 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Hemophilia A by Pfizer, or all of them as a file.
02

Study summary

This study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of multiple subcutaneous and/or intravenous doses of PF-06741086 in subjects with severe hemophilia.

03

Conditions studied

  • Hemophilia A or B

Browse trials for

Keywords

  • hemophilia
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Severe hemophilia A or B (Factor VIII or Factor IX activity ≤ 1%), including patients with inhibitors to Factor VIII or Factor IX
  • Episodic (on-demand) treatment regimen prior to screening
  • At least 6 acute bleeding episodes during the 6-month period prior to screening

Exclusion criteria

Exclusion Criteria:

  • Known coronary artery, thrombotic, or ischemic disease
  • Currently receiving treatment for acute bleeding episodes with APCC and cannot substitute treatment with rFVIIa
05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    PF-06741086 (Cohort 1)

    Biological: PF-06741086

  • Experimental
    PF-06741086 (Cohort 2)

    Biological: PF-06741086

  • Experimental
    PF-06741086 (Cohort 3)

    Biological: PF-06741086

  • Experimental
    PF-06741086 (Cohort 4)

    Biological: PF-06741086

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. A serious adverse event (SAE) was any untoward medical occurrence at any dose that resulted in death; was life threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect. AEs included both SAEs and non-serious AEs. TEAEs were AEs occurred following the start of treatment or AEs increasing in severity during treatment. Severe TEAEs were TEAEs that interfered significantly with participants' usual function. Treatment-related TEAEs were determined by the investigator.

    Time frame: Study Day 1 to Day 113 Visit

  2. Number of Participants Discontinued From Study Due to TEAEs

    An AE was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. TEAEs were AEs occurred following the start of treatment or AEs increasing in severity during treatment. Treatment-related TEAEs were determined by the investigator.

    Time frame: Study Day 1 to Day 113 Visit

  3. Number of Participants With Abnormal Laboratory Findings-Hematology

    Hematology evaluation included: hemoglobin, hematocrit, erythrocytes, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils and monocytes. Predefined criteria for hemoglobin and hematocrit: \<0.8\*lower limit of normal (LLN) or \<0.8\*Baseline(Baseline \<1.0\*LLN); for platelets: \<100,000\*10\^3/mm\^3 or \<= 0.77\*Baseline (Baseline \<1.0\*LLN).

    Time frame: Baseline to Study Day 113 Visit

  4. Number of Participants With Abnormal Laboratory Findings-Clinical Chemistry

    Clinical chemistry evaluation included bilirubin, direct and indirect bilirubin, aspartate aminotransferase, alanine aminotransferase, gamma glutamyl transferase, alkaline phosphatase, protein, albumin, urea nitrogen, creatinine, urate, triglycerides, sodium, potassium, chloride, calcium, bicarbonate, glucose, creatine kinase, troponin I, cholesterol and fibrinogen.

    Time frame: Baseline to Study Day 113

  5. Number of Participants With Abnormal Laboratory Findings-Urinalysis

    Urinalysis included: pH, urine glucose, ketones, urine protein, urine hemoglobin, urobilinogen, urine bilirubin, nitrite, leukocyte esterase, urine erythrocytes, urine leukocytes and bacteria.

    Time frame: Baseline to Study Day 113 Visit

  6. Change From Baseline for Globulin by Dose Cohort

    Blood samples were obtained to determine globulin level in serum, total globulin was derived as total protein other than albumin.

    Time frame: Baseline, Study Day 8, 15, 22, 29, 57, 85 and 113.

  7. Change From Baseline for Prothrombin International Normalized Ratio (PT/INR) by Dose Cohort

    Blood samples were obtained to evaluate this ratio. The prothrombin time (PT) is a test that helps evaluate your ability to appropriately form blood clots. The international normalized ratio (INR) is a calculation based on results of a PT that is used to monitor individuals who are being treated with the blood-thinning medication (anticoagulant) warfarin (Coumadin®).

    Time frame: Baseline, Study Day 8, 15, 22, 29, 57, 85 and 113.

  8. Change From Baseline for Activated Partial Thromboplastin Time (aPTT) by Dose Cohort

    The activated partial thromboplastin time (aPTT) is a screening test that helps evaluate a person's ability to appropriately form blood clots. It measures the number of seconds it takes for a clot to form in a sample of blood after substances (reagents) are added. Blood sample were obtained to evaluate aPTT.

    Time frame: Baseline, Study Day 8, 15, 22, 29, 57, 85 and 113.

  9. Change From Baseline for Fibrinogen by Dose Cohort

    Fibrinogen is a protein, specifically a clotting factor (factor I), that is essential for proper blood clot formation. Blood samples were obtained to evaluate the amount of fibrinogen.

    Time frame: Baseline, Study Day 8, 15, 22, 29, 57, 85 and 113.

  10. Change From Baseline for Antithrombin III by Dose Cohort

    Antithrombin (AT) is a protein produced by the liver that helps regulate blood clot formation (i.e., a naturally-occurring mild blood thinner). Blood samples were collected to measure the activity (function) and the amount (quantity) of antithrombin in an individual's blood is used to evaluate the person for excessive blood clotting.

    Time frame: Baseline, Study Day 8, 15, 22 and 29.

  11. Change From Baseline for Troponin I by Dose Cohort

    Blood samples were collected to measure the level of cardiac-specific troponin I in the blood to help detect heart injury.

    Time frame: Baseline, Study Day 8, 15, 22, 29, 57 and 85.

  12. Number of Participants With Vital Signs Data Meeting Pre-specified Criteria

    Criteria for potentially clinically important findings in vital signs data were defined as: 1) supine systolic blood pressure (BP): value \<90 mm Hg or change \>=30 mm Hg increase; 2) Supine diastolic BP: value \<50 mm Hg or change \>=20 mm Hg increase; 3) Supine pulse rate: value \<40 beats/min or \>120 beats/min.

    Time frame: Baseline to Study Day 113 Visit

  13. Number of Participants With Electrocardiogram (ECG) Change Meeting Pre-specified Criteria

    Criteria for potentially clinically important changes in ECG were defined as: PR interval baseline \>200 msec and increase of \>=25%; PR interval baseline \<=200 msec and increase of \>=50%; QRS interval increase of \>=50%. Only the number of participants meeting pre-defined criteria was reported below.

    Time frame: Baseline to Study Day 29 Visit.

  14. Number of Participants With Clinically Significant Changes in Physical Examination Findings

    Physical examination included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. Clinical significance was judged by the investigator.

    Time frame: Baseline to Study Day 113 Visit

  15. Number of Participants With Infusion and Injection Site Reactions

    Infusion and injection site reactions included: injection site bruising, injection site erythema, injection site haemorrhage, injection site induration, injection site pain, injection site pruritus, injection site swelling and injection site warmth. Grade of severity was defined as follows: Mild: Transient or mild discomfort (\< 48 hours); no medical intervention/therapy required. Moderate: Mild to moderate limitation in activity - some assistance may be needed; no or minimal medical intervention/therapy required. Severe: Marked limitation in activity, some assistance usually required; medical intervention/therapy required, hospitalizations possible.

    Time frame: Baseline to Study Day 113 Visit

Secondary outcomes

  1. Annualized Bleeding Rate (ABR)

    Pre-treatment ABR = number of bleeding episodes within 6 months prior to study enrollment (total number of bleeding episodes in hemophilia history CRF) × 2; On-study ABR = number of bleeding episodes occurred within 9 days after the last dose / (\[last dose date + 9 - first dose date + 1\] / 365.25) The historical On Demand group was constructed using the following internal Pfizer studies: ReFacto AF 3082B2-4432 (B1831004), BeneFIX B1821010, and BeneFIX 3090A1-400 (B1821004). Participants who were on On Demand treatment in B1831004, as well as data from the On Demand period in B1821004 and B1821010 were used to construct the historical On Demand group. The resulting dataset were further filtered to match the key inclusion/exclusion criteria of Study B7841002 based on age and factor activity (18 \<=age \<=65 and factor activity \<=1%).

    Time frame: Pre-treatment: within 6 months prior to study enrollment; On-study: Day 1 to 9 days after the last dose (Day 78)

  2. Plasma PF-06741086 Concentrations

    Plasma PF-06741086 concentrations were analyzed using a validated, sensitive and specific electrochemiluminescence (ECL) method.

    Time frame: pre-dose on Study Day 1, 24hours (h), 72h post Study Day 1 dosing, pre-dose on Study Day 8, 15 and 22, pre-dose on Study Day 29, 24h, 96h post Study Day 29 dosing, pre-dose on Study Day 57, 168h, 840h post Study Day 57 dosing

  3. Area Under the Concentration-time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of PF-06741086

    AUClast was calculated by linear/Log trapezoidal method.

    Time frame: Pre-dose on Day 1, 24 and 96 hours post Day 1 dosing

  4. Maximum Plasma Concentration (Cmax) of PF-06741086

    Cmax was observed directly from data.

    Time frame: Pre-dose on Day 1, 24 and 96 hours post Day 1 dosing, pre-dose on Day 29, 24 and 96 hours post Day 29 dosing

  5. Lowest Concentration Observed During the Dosing Interval (Cmin) of PF-06741086

    Cmin was observed directly from data.

    Time frame: Pre-dose on Day 1, 24 and 96 hours post Day 1 dosing, pre-dose on Day 29, 24 and 96 hours post Day 29 dosing

  6. Time to Reach Maximum Plasma Concentration (Tmax) of PF-06741086

    Tmax was observed directly from data as time of first occurrence.

    Time frame: Pre-dose on Day 1, 24 and 96 hours post Day 1 dosing, pre-dose on Day 29, 24 and 96 hours post Day 29 dosing

  7. Area Under the Serum Concentration-time Curve Over the Dosing Interval Tau (AUCtau) of PF-06741086

    The dosing interval tau was 1 week. AUCtau was obtained by linear/log trapezoidal method.

    Time frame: Pre-dose on Day 29, 24 and 96 hours post Day 29 dosing

  8. Apparent Clearance After Oral Dose (CL/F) of PF-06741086

    CL/F was calculated by dose/AUCtau.

    Time frame: Pre-dose on Day 29, 24 and 96 hours post Day 29 dosing

  9. Change From Baseline in Total Tissue Factor Pathway Inhibitor (TFPI)

    Total amount of tissue factor pathway inhibitor (TFPI) (bound and unbound) in plasma. TFPI is a protease inhibitor which acts as an antagonist of the extrinsic coagulation pathway via inhibition of tissue factor activated coagulation factor VII (FVIIa) and activated factor X (FXa). Human plasma samples were analyzed for total TFPI concentrations using a validated, sensitive and specific high-performance liquid chromatography tandem mass spectrometric method (LC-MS/MS). Mixed model repeated measures (MMRM) was used to analyze the change from baseline on TFPI.

    Time frame: Baseline, Study Day 2, 4, 8, 15, 22, 29, 30, 33, 57, 85 and 113

  10. Change From Baseline in Thrombin Generation (TGA) Lag Time

    An ex vivo pharmacodynamic measure of thrombin generation (initiation of thrombin generation), the lag time is the time needed to form the first traces of thrombin.

    Time frame: Baseline, Study Day 2, 4, 8, 15, 22, 29, 30, 33, 57, 85 and 113

  11. Change From Baseline in Thrombin Generation (TGA) Peak

    An ex vivo pharmacodynamic measure of thrombin generation (initiation of thrombin generation). The peak represents the highest thrombin concentration that can be generated. There may be patients who reach the peak faster or slower than others and this may represent hyper- or hypocoagulability, respectively.

    Time frame: Baseline, Study Day 2, 4, 8, 15, 22, 29, 30, 33, 57, 85 and 113

  12. Change From Baseline in Endogenous Thrombin Generation (TGA) Potential

    An ex vivo pharmacodynamic measure of thrombin generation. The endogenous TGA potential represents the total amount of active thrombin formed during thrombin generation and the peak height the maximal amount of thrombin formed.

    Time frame: Baseline, Study Day 2, 4, 8, 15, 22, 29, 30, 33, 57, 85 and 113

  13. Change From Baseline in Prothrombin Fragments 1 + 2

    An in vivo pharmacodynamic measure of thrombin generation (prothrombin cleavage). Prothrombin fragment 1+2 (F 1+2) is the amino terminus fragment of the prothrombin molecule. It is a polypeptide with a half-life of approximately 90 minutes. F 1+2 is released from prothrombin when prothrombin is converted to thrombin by the prothrombinase complex.

    Time frame: Baseline, Study Day 2, 4, 8, 15, 22, 29, 30, 33, 57, 85 and 113

  14. Change From Baseline in D-Dimer

    An in vivo pharmacodynamic measure of thrombin generation (fibrin degradation). D-dimer is a fibrin degradation product, a small protein fragment present in the blood after a blood clot is degraded by fibrinolysis. D-dimer is one of the protein fragments produced when a blood clot gets dissolved in the body. It is normally undetectable or detectable at a very low level unless the body is forming and breaking down blood clots. Then, its level in the blood can significantly rise.

    Time frame: Baseline, Study Day 2, 4, 8, 15, 22, 29, 30, 33, 57, 85 and 113

  15. Change From Baseline in Dilute Prothrombin Time

    An ex vivo pharmacodynamic measure of thrombin generation (via extrinsic pathway). Clotting time is measured using a dilute prothrombin time reagent consisting of a unique formulation of relipidated recombinant tissue factor and calcium.

    Time frame: Baseline, Study Day 2, 4, 8, 15, 22, 29, 30, 33, 57, 85 and 113

  16. Number of Participants Who Tested Positive for Anti-PF-06741086 Antibody (ADA)

    Human plasma ADA samples were analyzed for the detection of anti PF-06741086 antibodies by using semi-quantitative electrochemiluminescence (ECL) method. The criterion for positive result of ADA samples was ADA titer \>=1.53. Treatment induced are negative prior to dosing and become positive during/after dosing. Treatment boosted are positive prior to dosing but titer increases during/after dosing.

    Time frame: Baseline up to Study Day 113

  17. Number of Participants Who Tested Positive for Neutralizing Antibody (NAb)

    Human plasma NAb samples were analyzed for the presence or absence of NAb to PF-06741086 using semi-quantitative electrochemiluminescence (ECL) method. Treatment induced are negative prior to dosing and become positive during/after dosing. Treatment boosted are positive prior to dosing but titer increases during/after dosing.

    Time frame: Baseline up to Study Day 113

07

Results

Posted Dec 4, 2019

Participant flow

Participant flow — Overall Study
MilestonePF-06741086 300 mg SC QW Non-InhibitorPF-06741086 300 mg SC Loading + 150 mg SC QW Non-InhibitorPF-06741086 450 mg SC QW Non-InhibitorPF-06741086 300 mg SC QW Inhibitor
Started7667
Completed7566
Not completed0101
Withdrew: Adverse event0101

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. A serious adverse event (SAE) was any untoward medical occurrence at any dose that resulted in death; was life threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect. AEs included both SAEs and non-serious AEs. TEAEs were AEs occurred following the start of treatment or AEs increasing in severity during treatment. Severe TEAEs were TEAEs that interfered significantly with participants' usual function. Treatment-related TEAEs were determined by the investigator.

Time frame:
Study Day 1 to Day 113 Visit
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsPF-06741086 300 mg SC QW Non-InhibitorPF-06741086 300 mg SC Loading + 150 mg SC QW Non-InhibitorPF-06741086 450 mg SC QW Non-InhibitorPF-06741086 300 mg SC QW InhibitorOverall PF-06741086 300 mg SCTotal
All-causalities TEAE74641121
Treatment-related TEAE4433714
All-causalities serious TEAE111124
Treatment-related serious TEAE000000
All-causalities Grade 3 or 4 TEAE002224
Treatment-related Grade 3 or 4 TEAE002224
PrimaryNumber of Participants Discontinued From Study Due to TEAEs

An AE was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. TEAEs were AEs occurred following the start of treatment or AEs increasing in severity during treatment. Treatment-related TEAEs were determined by the investigator.

Time frame:
Study Day 1 to Day 113 Visit
Reported as:
Count of participants · Participants
Number of Participants Discontinued From Study Due to TEAEs
ParticipantsPF-06741086 300 mg SC QW Non-InhibitorPF-06741086 300 mg SC Loading + 150 mg SC QW Non-InhibitorPF-06741086 450 mg SC QW Non-InhibitorPF-06741086 300 mg SC QW InhibitorOverall PF-06741086 300 mg SCTotal
All-causalities TEAE010112
Treatment-related TEAE010112
PrimaryNumber of Participants With Abnormal Laboratory Findings-Hematology

Hematology evaluation included: hemoglobin, hematocrit, erythrocytes, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils and monocytes. Predefined criteria for hemoglobin and hematocrit: \<0.8\*lower limit of normal (LLN) or \<0.8\*Baseline(Baseline \<1.0\*LLN); for platelets: \<100,000\*10\^3/mm\^3 or \<= 0.77\*Baseline (Baseline \<1.0\*LLN).

Time frame:
Baseline to Study Day 113 Visit
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Laboratory Findings-Hematology
ParticipantsPF-06741086 300 mg SC QW Non-InhibitorPF-06741086 300 mg SC Loading + 150 mg SC QW Non-InhibitorPF-06741086 450 mg SC QW Non-InhibitorPF-06741086 300 mg SC QW InhibitorOverall PF-06741086 300 mg SCTotal
Hemoglobin meeting pre-defined criteria000000
Hematocrit meeting pre-defined criteria000000
Erythrocytes <0.8*LLN000000
Platelets meeting pre-defined criteria000000
Leukocytes <0.6*LLN000000
Leukocytes >1.5*upper limit of normal (ULN)000000
Lymphocytes <0.8*LLN010001
Lymphocytes >1.2*ULN000000
Neutrophils <0.8*LLN120013
Neutrophils >1.2*ULN000000
Basophils >1.2*ULN000000
Eosinophils >1.2*ULN000000
Monocytes >1.2*ULN000000
PrimaryNumber of Participants With Abnormal Laboratory Findings-Clinical Chemistry

Clinical chemistry evaluation included bilirubin, direct and indirect bilirubin, aspartate aminotransferase, alanine aminotransferase, gamma glutamyl transferase, alkaline phosphatase, protein, albumin, urea nitrogen, creatinine, urate, triglycerides, sodium, potassium, chloride, calcium, bicarbonate, glucose, creatine kinase, troponin I, cholesterol and fibrinogen.

Time frame:
Baseline to Study Day 113
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Laboratory Findings-Clinical Chemistry
ParticipantsPF-06741086 300 mg SC QW Non-InhibitorPF-06741086 300 mg SC Loading + 150 mg SC QW Non-InhibitorPF-06741086 450 mg SC QW Non-InhibitorPF-06741086 300 mg SC QW InhibitorOverall PF-06741086 300 mg SCTotal
Bilirubin >1.5*ULN000000
Direct Bilirubin >1.5*ULN000000
Indirect Bilirubin >1.5*ULN000000
Aspartate Aminotransferase >3.0*ULN001001
Alanine Aminotransferase >3.0*ULN111013
Gamma Glutamyl Transferase >3.0*ULN010001
Alkaline Phosphatase000000
Protein <0.8*LLN000000
Protein >1.2*ULN000000
Albumin <0.8*LLN000000
Albumin >1.2*ULN000000
Urea Nitrogen >1.3*ULN000000
Creatinine >1.3*ULN000000
Urate >1.2*ULN000222
Triglycerides >1.3*ULN000000
Sodium <0.95*LLN000000
Sodium >1.05*ULN000000
Potassium <0.9*LLN100011
Potassium >1.1*ULN000000
Chloride <0.9*LLN000000
Chloride >1.1*ULN000000
Calcium <0.9*LLN000000
Calcium >1.1*ULN000000
Bicarbonate <0.9*LLN210023
Bicarbonate >1.1*ULN000000
Glucose <0.6*LLN000000
Glucose >1.5*ULN002113
Creatine Kinase >2.0*ULN000000
Troponin I >1.0*ULN110234
Cholesterol >1.3*ULN000000
Fibrinogen <=0.5*LLN or <=0.5*baseline000111
PrimaryNumber of Participants With Abnormal Laboratory Findings-Urinalysis

Urinalysis included: pH, urine glucose, ketones, urine protein, urine hemoglobin, urobilinogen, urine bilirubin, nitrite, leukocyte esterase, urine erythrocytes, urine leukocytes and bacteria.

Time frame:
Baseline to Study Day 113 Visit
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Laboratory Findings-Urinalysis
ParticipantsPF-06741086 300 mg SC QW Non-InhibitorPF-06741086 300 mg SC Loading + 150 mg SC QW Non-InhibitorPF-06741086 450 mg SC QW Non-InhibitorPF-06741086 300 mg SC QW InhibitorOverall PF-06741086 300 mg SCTotal
pH (Scalar) <4.5000000
pH (Scalar) >8000000
Urine glucose >=1001001
Ketones (Scalar) >=1001112
Urine protein >=1000111
Urine hemoglobin (Scalar) >=1000000
Urobilinogen >=1000000
Urine bilirubin (Scalar) >=1000000
Nitrite (Scalar) >=1000000
Leukocyte esterase (Scalar) >=1110123
Urine erythrocytes (/HPF) >=20000000
Urine leukocytes (/HPF) >=20010112
Bacteria (/HPF) >20000000
PrimaryChange From Baseline for Globulin by Dose Cohort

Blood samples were obtained to determine globulin level in serum, total globulin was derived as total protein other than albumin.

Time frame:
Baseline, Study Day 8, 15, 22, 29, 57, 85 and 113.
Reported as:
Mean · gram/liter
Change From Baseline for Globulin by Dose Cohort
gram/literPF-06741086 300 mg SC QW Non-InhibitorPF-06741086 300 mg SC Loading + 150 mg SC QW Non-InhibitorPF-06741086 450 mg SC QW Non-InhibitorPF-06741086 300 mg SC QW InhibitorOverall PF-06741086 300 mg SCTotal
Globulin, Change at Day 8-0.3 ± 3.04-1.7 ± 3.93-1.3 ± 2.730.4 ± 2.510.1 ± 2.70-0.7 ± 3.01
Globulin, Change at Day 15-0.7 ± 2.06-0.8 ± 2.32-1.3 ± 2.50-1.3 ± 3.35-1.0 ± 2.69-1.0 ± 2.47
Globulin, Study Day 22-1.6 ± 2.82-0.5 ± 1.52-1.5 ± 3.08-0.6 ± 4.12-1.1 ± 3.43-1.0 ± 2.93
Globulin, Change at Day 29-0.3 ± 3.27-0.3 ± 3.080.2 ± 1.10-1.3 ± 2.75-0.8 ± 2.91-0.5 ± 2.62
Globulin, Change at Day 570.7 ± 3.721.8 ± 2.99-0.3 ± 1.63-0.7 ± 2.940.0 ± 3.280.4 ± 2.90
Globulin, Change at Day 851.3 ± 3.15-1.4 ± 4.77-0.5 ± 3.021.0 ± 2.611.2 ± 2.790.2 ± 3.35
Globulin, Change at Day 113-0.3 ± 3.15-1.2 ± 4.670.5 ± 2.65-0.8 ± 3.06-0.5 ± 2.99-0.5 ± 3.33
PrimaryChange From Baseline for Prothrombin International Normalized Ratio (PT/INR) by Dose Cohort

Blood samples were obtained to evaluate this ratio. The prothrombin time (PT) is a test that helps evaluate your ability to appropriately form blood clots. The international normalized ratio (INR) is a calculation based on results of a PT that is used to monitor individuals who are being treated with the blood-thinning medication (anticoagulant) warfarin (Coumadin®).

Time frame:
Baseline, Study Day 8, 15, 22, 29, 57, 85 and 113.
Reported as:
Mean · Ratio
Change From Baseline for Prothrombin International Normalized Ratio (PT/INR) by Dose Cohort
RatioPF-06741086 300 mg SC QW Non-InhibitorPF-06741086 300 mg SC Loading + 150 mg SC QW Non-InhibitorPF-06741086 450 mg SC QW Non-InhibitorPF-06741086 300 mg SC QW InhibitorOverall PF-06741086 300 mg SCTotal
PT/INR, Change at Day 8-0.03 ± 0.049-0.02 ± 0.0410.05 ± 0.1380.03 ± 0.1380.00 ± 0.1040.01 ± 0.102
PT/INR, Change at Day 150.03 ± 0.0760.00 ± 0.0630.02 ± 0.0410.00 ± 0.0820.01 ± 0.0770.01 ± 0.065
PT/INR, Change at Day 220.03 ± 0.0950.00 ± 0.063-0.02 ± 0.041-0.01 ± 0.0690.01 ± 0.0830.00 ± 0.069
PT/INR, Change at Day 290.03 ± 0.082-0.02 ± 0.0410.00 ± 0.0630.00 ± 0.1150.02 ± 0.0990.00 ± 0.079
PT/INR, Change at Day 570.00 ± 0.126-0.03 ± 0.0520.00 ± 0.063-0.02 ± 0.075-0.01 ± 0.100-0.01 ± 0.080
PT/INR, Change at Day 85-0.01 ± 0.1070.04 ± 0.152-0.02 ± 0.075-0.03 ± 0.082-0.02 ± 0.093-0.01 ± 0.102
PT/INR, Change at Day 1130.06 ± 0.127-0.03 ± 0.052-0.05 ± 0.0580.07 ± 0.0520.06 ± 0.0960.02 ± 0.094
PrimaryChange From Baseline for Activated Partial Thromboplastin Time (aPTT) by Dose Cohort

The activated partial thromboplastin time (aPTT) is a screening test that helps evaluate a person's ability to appropriately form blood clots. It measures the number of seconds it takes for a clot to form in a sample of blood after substances (reagents) are added. Blood sample were obtained to evaluate aPTT.

Time frame:
Baseline, Study Day 8, 15, 22, 29, 57, 85 and 113.
Reported as:
Mean · seconds
Change From Baseline for Activated Partial Thromboplastin Time (aPTT) by Dose Cohort
secondsPF-06741086 300 mg SC QW Non-InhibitorPF-06741086 300 mg SC Loading + 150 mg SC QW Non-InhibitorPF-06741086 450 mg SC QW Non-InhibitorPF-06741086 300 mg SC QW InhibitorOverall PF-06741086 300 mg SCTotal
aPTT, Change at Day 88.49 ± 17.01710.63 ± 11.63411.03 ± 15.467-12.26 ± 7.082-1.89 ± 16.5123.98 ± 16.079
aPTT, Change at Day 159.50 ± 10.90712.50 ± 15.3031.20 ± 20.075-10.26 ± 6.757-0.38 ± 13.4572.96 ± 15.825
aPTT, Change at Day 2214.79 ± 10.79912.15 ± 15.2324.50 ± 9.765-11.77 ± 11.2471.51 ± 17.3814.65 ± 15.543
aPTT, Change at Day 2913.42 ± 11.1029.85 ± 15.99910.13 ± 10.250-12.87 ± 11.390-0.74 ± 17.3864.41 ± 16.009
aPTT, Change at Day 5713.65 ± 13.37814.25 ± 14.0617.82 ± 11.580-9.13 ± 8.3902.26 ± 15.9666.65 ± 14.817
aPTT, Change at Day 859.00 ± 10.9283.84 ± 18.0897.68 ± 14.733-7.57 ± 10.1241.35 ± 13.2783.45 ± 14.257
aPTT, Change at Day 1138.46 ± 23.3910.78 ± 16.332-0.97 ± 26.6339.37 ± 20.2658.88 ± 21.0935.05 ± 20.500
PrimaryChange From Baseline for Fibrinogen by Dose Cohort

Fibrinogen is a protein, specifically a clotting factor (factor I), that is essential for proper blood clot formation. Blood samples were obtained to evaluate the amount of fibrinogen.

Time frame:
Baseline, Study Day 8, 15, 22, 29, 57, 85 and 113.
Reported as:
Mean · milligram/deciliter
Change From Baseline for Fibrinogen by Dose Cohort
milligram/deciliterPF-06741086 300 mg SC QW Non-InhibitorPF-06741086 300 mg SC Loading + 150 mg SC QW Non-InhibitorPF-06741086 450 mg SC QW Non-InhibitorPF-06741086 300 mg SC QW InhibitorOverall PF-06741086 300 mg SCTotal
Fibrinogen, Change at Day 8-49.7 ± 28.72-59.7 ± 38.20-3.5 ± 24.16-54.4 ± 59.58-52.1 ± 45.00-42.6 ± 44.14
Fibrinogen, Change at Day 15-59.4 ± 41.28-51.0 ± 31.84-8.3 ± 25.96-85.6 ± 94.86-72.5 ± 71.58-52.7 ± 60.78
Fibrinogen, Change at Day 22-72.0 ± 40.76-36.8 ± 44.93-33.2 ± 32.41-87.9 ± 115.49-79.9 ± 83.61-59.2 ± 69.08
Fibrinogen, Change at Day 29-84.7 ± 43.53-40.0 ± 26.57-40.3 ± 20.99-99.9 ± 106.59-92.8 ± 80.82-67.6 ± 65.01
Fibrinogen, Change at Day 57-33.5 ± 85.8110.0 ± 79.34-21.3 ± 24.23-58.7 ± 71.81-46.1 ± 76.57-25.9 ± 69.68
Fibrinogen, Change at Day 85-49.9 ± 47.93-39.4 ± 63.27-10.5 ± 44.94-40.8 ± 74.28-45.7 ± 58.91-35.6 ± 56.31
Fibrinogen, Change at Day 113-38.6 ± 44.48-5.2 ± 29.3423.5 ± 26.80-61.7 ± 126.18-49.2 ± 88.13-25.1 ± 73.56
PrimaryChange From Baseline for Antithrombin III by Dose Cohort

Antithrombin (AT) is a protein produced by the liver that helps regulate blood clot formation (i.e., a naturally-occurring mild blood thinner). Blood samples were collected to measure the activity (function) and the amount (quantity) of antithrombin in an individual's blood is used to evaluate the person for excessive blood clotting.

Time frame:
Baseline, Study Day 8, 15, 22 and 29.
Reported as:
Mean · Percentage of activity of AT in plasma
Change From Baseline for Antithrombin III by Dose Cohort
Percentage of activity of AT in plasmaPF-06741086 300 mg SC QW Non-InhibitorPF-06741086 300 mg SC Loading + 150 mg SC QW Non-InhibitorPF-06741086 450 mg SC QW Non-InhibitorPF-06741086 300 mg SC QW InhibitorOverall PF-06741086 300 mg SCTotal
Antithrombin III, Change at Day 82.1 ± 5.18-1.8 ± 7.053.7 ± 7.58-7.3 ± 9.32-2.6 ± 8.74-1.0 ± 8.24
Antithrombin III, Change at Day 152.4 ± 16.960.5 ± 8.14-15.3 ± 16.45-6.9 ± 6.74-2.2 ± 13.30-4.6 ± 14.02
Antithrombin III, Change at Day 22-7.6 ± 17.555.2 ± 12.69-5.3 ± 9.97-4.4 ± 17.61-6.0 ± 16.97-3.3 ± 14.97
Antithrombin III, Change at Day 29-0.8 ± 8.04-4.3 ± 11.55-10.3 ± 15.45-12.7 ± 12.96-7.2 ± 12.20-7.3 ± 12.51
PrimaryChange From Baseline for Troponin I by Dose Cohort

Blood samples were collected to measure the level of cardiac-specific troponin I in the blood to help detect heart injury.

Time frame:
Baseline, Study Day 8, 15, 22, 29, 57 and 85.
Reported as:
Mean · nanogram/milliliter
Change From Baseline for Troponin I by Dose Cohort
nanogram/milliliterPF-06741086 300 mg SC QW Non-InhibitorPF-06741086 300 mg SC Loading + 150 mg SC QW Non-InhibitorPF-06741086 450 mg SC QW Non-InhibitorPF-06741086 300 mg SC QW InhibitorOverall PF-06741086 300 mg SCTotal
Troponin I, Change at Day 80 ± 00 ± 00 ± 00 ± 00 ± 00 ± 0
Troponin I, Change at Day 150 ± 00 ± 00 ± 00 ± 00 ± 00 ± 0
Troponin I, Change at Day 220.0042 ± 0.010210 ± 00 ± 00.0142 ± 0.034700.0092 ± 0.024940.0052 ± 0.01907
Troponin I, Change at Day 290 ± 00.0113 ± 0.022500 ± 00.0121 ± 0.032130.0065 ± 0.023570.0059 ± 0.02010
Troponin I, Change at Day 57—0———0
Troponin I, Change at Day 850———00
PrimaryNumber of Participants With Vital Signs Data Meeting Pre-specified Criteria

Criteria for potentially clinically important findings in vital signs data were defined as: 1) supine systolic blood pressure (BP): value \<90 mm Hg or change \>=30 mm Hg increase; 2) Supine diastolic BP: value \<50 mm Hg or change \>=20 mm Hg increase; 3) Supine pulse rate: value \<40 beats/min or \>120 beats/min.

Time frame:
Baseline to Study Day 113 Visit
Reported as:
Count of participants · Participants
Number of Participants With Vital Signs Data Meeting Pre-specified Criteria
ParticipantsPF-06741086 300 mg SC QW Non-InhibitorPF-06741086 300 mg SC Loading + 150 mg SC QW Non-InhibitorPF-06741086 450 mg SC QW Non-InhibitorPF-06741086 300 mg SC QW InhibitorOverall PF-06741086 300 mg SCTotal
Supine systolic BP value <90 mm Hg000000
Supine systolic BP change >=30 mm Hg increase011002
Supine diastolic BP value <50 mm Hg000000
Supine diastolic BP change >=20 mm Hg increase010001
Supine pulse rate value <40 beats/min000000
Supine pulse rate value >120 beats/min000000
PrimaryNumber of Participants With Electrocardiogram (ECG) Change Meeting Pre-specified Criteria

Criteria for potentially clinically important changes in ECG were defined as: PR interval baseline \>200 msec and increase of \>=25%; PR interval baseline \<=200 msec and increase of \>=50%; QRS interval increase of \>=50%. Only the number of participants meeting pre-defined criteria was reported below.

Time frame:
Baseline to Study Day 29 Visit.
Reported as:
Count of participants · Participants
Number of Participants With Electrocardiogram (ECG) Change Meeting Pre-specified Criteria
ParticipantsPF-06741086 300 mg SC QW Non-InhibitorPF-06741086 300 mg SC Loading + 150 mg SC QW Non-InhibitorPF-06741086 450 mg SC QW Non-InhibitorPF-06741086 300 mg SC QW InhibitorOverall PF-06741086 300 mg SCTotal
Number of Participants With Electrocardiogram (ECG) Change Meeting Pre-specified Criteria000000
PrimaryNumber of Participants With Clinically Significant Changes in Physical Examination Findings

Physical examination included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. Clinical significance was judged by the investigator.

Time frame:
Baseline to Study Day 113 Visit
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Physical Examination Findings
ParticipantsPF-06741086 300 mg SC QW Non-InhibitorPF-06741086 300 mg SC Loading + 150 mg SC QW Non-InhibitorPF-06741086 450 mg SC QW Non-InhibitorPF-06741086 300 mg SC QW InhibitorOverall PF-06741086 300 mg SCTotal
Number of Participants With Clinically Significant Changes in Physical Examination Findings000000
PrimaryNumber of Participants With Infusion and Injection Site Reactions

Infusion and injection site reactions included: injection site bruising, injection site erythema, injection site haemorrhage, injection site induration, injection site pain, injection site pruritus, injection site swelling and injection site warmth. Grade of severity was defined as follows: Mild: Transient or mild discomfort (\< 48 hours); no medical intervention/therapy required. Moderate: Mild to moderate limitation in activity - some assistance may be needed; no or minimal medical intervention/therapy required. Severe: Marked limitation in activity, some assistance usually required; medical intervention/therapy required, hospitalizations possible.

Time frame:
Baseline to Study Day 113 Visit
Reported as:
Count of participants · Participants
Number of Participants With Infusion and Injection Site Reactions
ParticipantsPF-06741086 300 mg SC QW Non-InhibitorPF-06741086 300 mg SC Loading + 150 mg SC QW Non-InhibitorPF-06741086 450 mg SC QW Non-InhibitorPF-06741086 300 mg SC QW InhibitorOverall PF-06741086 300 mg SCTotal
All-causality Mild310145
Treatment-related Mild310145
All-causality Moderate000111
Treatment-related Moderate000111
All-causality Severe002002
Treatment-related Severe002002
SecondaryAnnualized Bleeding Rate (ABR)

Pre-treatment ABR = number of bleeding episodes within 6 months prior to study enrollment (total number of bleeding episodes in hemophilia history CRF) × 2; On-study ABR = number of bleeding episodes occurred within 9 days after the last dose / (\[last dose date + 9 - first dose date + 1\] / 365.25) The historical On Demand group was constructed using the following internal Pfizer studies: ReFacto AF 3082B2-4432 (B1831004), BeneFIX B1821010, and BeneFIX 3090A1-400 (B1821004). Participants who were on On Demand treatment in B1831004, as well as data from the On Demand period in B1821004 and B1821010 were used to construct the historical On Demand group. The resulting dataset were further filtered to match the key inclusion/exclusion criteria of Study B7841002 based on age and factor activity (18 \<=age \<=65 and factor activity \<=1%).

Time frame:
Pre-treatment: within 6 months prior to study enrollment; On-study: Day 1 to 9 days after the last dose (Day 78)
Reported as:
Mean · Bleeding episodes per year
Annualized Bleeding Rate (ABR)
Bleeding episodes per yearPF-06741086 300 mg SC QW Non-InhibitorPF-06741086 300 mg SC Loading + 150 mg SC QW Non-InhibitorPF-06741086 450 mg SC QW Non-InhibitorPF-06741086 300 mg SC QW InhibitorOverall PF-06741086 300 mg SCTotal
Pre-Treatment23.00 ± 7.45714.67 ± 1.63320.33 ± 10.83817.33 ± 3.01120.17 ± 6.17718.83 ± 7.100
On-Study4.22 ± 3.7991.62 ± 2.5334.17 ± 6.4670.65 ± 1.6032.43 ± 3.3452.67 ± 4.092
Statistical analysis
  • PF-06741086 300 mg SC QW Non-Inhibitor · Negative Binomial Model · p = 0.0002 · Ratio: 0.15 · 80% CI 0.08 to 0.29
  • PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor · Negative Binomial Model · p = 0.0001 · Ratio: 0.05 · 80% CI 0.02 to 0.14
  • PF-06741086 450 mg SC QW Non-Inhibitor · Negative Binomial Model · p = 0.0002 · Ratio: 0.15 · 80% CI 0.08 to 0.29
  • PF-06741086 300 mg SC QW Inhibitor · Negative Binomial Model · p = 0.0005 · Ratio: 0.03 · 80% CI 0.01 to 0.10
  • Overall PF-06741086 300 mg SC · Negative Binomial Model · p = <0.0001 · Ratio: 0.09 · 80% CI 0.05 to 0.16
  • PF-06741086 300 mg SC QW Non-Inhibitor · Negative Binomial Model · p = <0.0001 · Ratio: 0.18 · 80% CI 0.11 to 0.31
  • PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor · Negative Binomial Model · p = 0.0002 · Ratio: 0.10 · 80% CI 0.04 to 0.22
  • PF-06741086 450 mg SC QW Non-Inhibitor · Negative Binomial Model · p = 0.0154 · Ratio: 0.20 · 80% CI 0.09 to 0.47
  • PF-06741086 300 mg SC QW Inhibitor · Negative Binomial Model · p = 0.0005 · Ratio: 0.04 · 80% CI 0.01 to 0.14
  • Overall PF-06741086 300 mg SC · Negative Binomial Model · p = <0.0001 · Ratio: 0.12 · 80% CI 0.08 to 0.20
SecondaryPlasma PF-06741086 Concentrations

Plasma PF-06741086 concentrations were analyzed using a validated, sensitive and specific electrochemiluminescence (ECL) method.

Time frame:
pre-dose on Study Day 1, 24hours (h), 72h post Study Day 1 dosing, pre-dose on Study Day 8, 15 and 22, pre-dose on Study Day 29, 24h, 96h post Study Day 29 dosing, pre-dose on Study Day 57, 168h, 840h post Study Day 57 dosing
Reported as:
Mean · nanogram/milliliter
Plasma PF-06741086 Concentrations
nanogram/milliliterPF-06741086 300 mg SC QW Non-InhibitorPF-06741086 300 mg SC Loading + 150 mg SC QW Non-InhibitorPF-06741086 450 mg SC QW Non-InhibitorPF-06741086 300 mg SC QW InhibitorOverall PF-06741086 300 mg SC
24h post Day 1 dosing12180 ± 8500.215620 ± 8055.311640 ± 4670.618130 ± 9111.315150 ± 9011.0
72h post Day 1 dosing17560 ± 1063720850 ± 8433.724270 ± 8018.920640 ± 8978.419100 ± 9591.3
Pre-dose on Day 811290 ± 1001914060 ± 6201.216700 ± 5689.111940 ± 4981.711610 ± 7609.2
Pre-dose on Day 1522850 ± 1514216680 ± 7668.828180 ± 1016324870 ± 5726.823860 ± 11048
Pre-dose on Day 2233010 ± 1972417900 ± 1050941200 ± 1750436450 ± 1043234600 ± 15590
Pre-dose on Day 2946180 ± 2135716780 ± 7939.759950 ± 3062541500 ± 1388443840 ± 17161
24h post Day 29 dosing66500 ± 2713523530 ± 8548.473780 ± 2242569920 ± 2790268210 ± 26010
96h post Day 29 dosing69130 ± 3045920680 ± 1158074950 ± 2753858150 ± 1875362860 ± 22794
Pre-dose on Day 5754580 ± 2902218260 ± 1506266480 ± 4552959140 ± 2437756860 ± 25382
168h post Day 57 dosing53890 ± 4348324800 ± 2994.487500 ± 3716366700 ± 2897160300 ± 35481
840h post Day 57 dosing586.6 ± 1318.4——90.00 ± 180.00406.0 ± 1056.1
SecondaryArea Under the Concentration-time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of PF-06741086

AUClast was calculated by linear/Log trapezoidal method.

Time frame:
Pre-dose on Day 1, 24 and 96 hours post Day 1 dosing
Reported as:
Geometric mean · nanogram*hour/milliliter
Area Under the Concentration-time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of PF-06741086
nanogram*hour/milliliterPF-06741086 300 mg SC QW Non-InhibitorPF-06741086 300 mg SC Loading + 150 mg SC QW Non-InhibitorPF-06741086 450 mg SC QW Non-InhibitorPF-06741086 300 mg SC QW InhibitorOverall PF-06741086 300 mg SC
Area Under the Concentration-time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of PF-067410861818000 ± 792675000 ± 412806000 ± 372495000 ± 402130000 ± 61
SecondaryMaximum Plasma Concentration (Cmax) of PF-06741086

Cmax was observed directly from data.

Time frame:
Pre-dose on Day 1, 24 and 96 hours post Day 1 dosing, pre-dose on Day 29, 24 and 96 hours post Day 29 dosing
Reported as:
Geometric mean · nanogram/milliliter
Maximum Plasma Concentration (Cmax) of PF-06741086
nanogram/milliliterPF-06741086 300 mg SC QW Non-InhibitorPF-06741086 300 mg SC Loading + 150 mg SC QW Non-InhibitorPF-06741086 450 mg SC QW Non-InhibitorPF-06741086 300 mg SC QW InhibitorOverall PF-06741086 300 mg SC
Cmax, Day 114880 ± 7019480 ± 4223070 ± 3719680 ± 5117110 ± 61
Cmax, Day 2961850 ± 4724150 ± 4473490 ± 3866070 ± 4463930 ± 43
SecondaryLowest Concentration Observed During the Dosing Interval (Cmin) of PF-06741086

Cmin was observed directly from data.

Time frame:
Pre-dose on Day 1, 24 and 96 hours post Day 1 dosing, pre-dose on Day 29, 24 and 96 hours post Day 29 dosing
Reported as:
Geometric mean · nanogram/milliliter
Lowest Concentration Observed During the Dosing Interval (Cmin) of PF-06741086
nanogram/milliliterPF-06741086 300 mg SC QW Non-InhibitorPF-06741086 300 mg SC Loading + 150 mg SC QW Non-InhibitorPF-06741086 450 mg SC QW Non-InhibitorPF-06741086 300 mg SC QW InhibitorOverall PF-06741086 300 mg SC
Cmin, Day 17980 ± 11213040 ± 4315660 ± 4411140 ± 419429 ± 78
Cmin, Day 2942120 ± 5215000 ± 5953630 ± 6139490 ± 3740790 ± 42
SecondaryTime to Reach Maximum Plasma Concentration (Tmax) of PF-06741086

Tmax was observed directly from data as time of first occurrence.

Time frame:
Pre-dose on Day 1, 24 and 96 hours post Day 1 dosing, pre-dose on Day 29, 24 and 96 hours post Day 29 dosing
Reported as:
Median · hours
Time to Reach Maximum Plasma Concentration (Tmax) of PF-06741086
hoursPF-06741086 300 mg SC QW Non-InhibitorPF-06741086 300 mg SC Loading + 150 mg SC QW Non-InhibitorPF-06741086 450 mg SC QW Non-InhibitorPF-06741086 300 mg SC QW InhibitorOverall PF-06741086 300 mg SC
Tmax, Day 170.0 (69.1 to 72.8)69.7 (68.2 to 71.1)71.6 (67.6 to 72.3)70.7 (22.8 to 167)70.1 (22.8 to 167)
Tmax, Day 2923.7 (23.1 to 94.2)23.7 (22.0 to 71.7)58.5 (23.3 to 97.0)22.8 (22.1 to 94.7)23.3 (22.1 to 94.7)
SecondaryArea Under the Serum Concentration-time Curve Over the Dosing Interval Tau (AUCtau) of PF-06741086

The dosing interval tau was 1 week. AUCtau was obtained by linear/log trapezoidal method.

Time frame:
Pre-dose on Day 29, 24 and 96 hours post Day 29 dosing
Reported as:
Geometric mean · nanogram*hour/milliliter
Area Under the Serum Concentration-time Curve Over the Dosing Interval Tau (AUCtau) of PF-06741086
nanogram*hour/milliliterPF-06741086 300 mg SC QW Non-InhibitorPF-06741086 300 mg SC Loading + 150 mg SC QW Non-InhibitorPF-06741086 450 mg SC QW Non-InhibitorPF-06741086 300 mg SC QW InhibitorOverall PF-06741086 300 mg SC
Area Under the Serum Concentration-time Curve Over the Dosing Interval Tau (AUCtau) of PF-067410869045000 ± 493309000 ± 5011090000 ± 439248000 ± 389146000 ± 41
SecondaryApparent Clearance After Oral Dose (CL/F) of PF-06741086

CL/F was calculated by dose/AUCtau.

Time frame:
Pre-dose on Day 29, 24 and 96 hours post Day 29 dosing
Reported as:
Geometric mean · milliliter/hour
Apparent Clearance After Oral Dose (CL/F) of PF-06741086
milliliter/hourPF-06741086 300 mg SC QW Non-InhibitorPF-06741086 300 mg SC Loading + 150 mg SC QW Non-InhibitorPF-06741086 450 mg SC QW Non-InhibitorPF-06741086 300 mg SC QW InhibitorOverall PF-06741086 300 mg SC
Apparent Clearance After Oral Dose (CL/F) of PF-0674108633.16 ± 4945.34 ± 5040.60 ± 4332.43 ± 3832.79 ± 41
SecondaryChange From Baseline in Total Tissue Factor Pathway Inhibitor (TFPI)

Total amount of tissue factor pathway inhibitor (TFPI) (bound and unbound) in plasma. TFPI is a protease inhibitor which acts as an antagonist of the extrinsic coagulation pathway via inhibition of tissue factor activated coagulation factor VII (FVIIa) and activated factor X (FXa). Human plasma samples were analyzed for total TFPI concentrations using a validated, sensitive and specific high-performance liquid chromatography tandem mass spectrometric method (LC-MS/MS). Mixed model repeated measures (MMRM) was used to analyze the change from baseline on TFPI.

Time frame:
Baseline, Study Day 2, 4, 8, 15, 22, 29, 30, 33, 57, 85 and 113
Reported as:
Mean · nanogram/milliliter
Change From Baseline in Total Tissue Factor Pathway Inhibitor (TFPI)
nanogram/milliliterPF-06741086 300 mg SC QW Non-InhibitorPF-06741086 300 mg SC Loading + 150 mg SC QW Non-InhibitorPF-06741086 450 mg SC QW Non-InhibitorPF-06741086 300 mg SC QW InhibitorOverall PF-06741086 300 mg SC
TFPI, Change at Day 23.9 ± 31.43-13.4 ± 17.178.2 ± 19.830.4 ± 46.812.1 ± 38.35
TFPI, Change at Day 439.4 ± 46.1043.2 ± 25.7674.0 ± 22.0386.0 ± 29.7162.7 ± 44.41
TFPI, Change at Day 842.7 ± 82.5272.4 ± 10.81120.5 ± 34.4155.9 ± 69.8449.3 ± 73.76
TFPI, Change at Day 15143.9 ± 107.5678.8 ± 43.36186.5 ± 52.80156.1 ± 83.87150.0 ± 92.88
TFPI, Change at Day 22256.1 ± 137.09110.0 ± 80.96301.5 ± 84.39223.3 ± 128.08239.7 ± 128.59
TFPI, Change at Day 29324.2 ± 127.46106.6 ± 77.56334.7 ± 120.67222.1 ± 135.29269.2 ± 136.83
TFPI, Change at Day 30363.8 ± 156.87115.6 ± 86.41347.8 ± 170.70286.7 ± 103.72325.3 ± 133.04
TFPI, Change at Day 33337.7 ± 129.05165.8 ± 35.20351.0 ± 161.54296.3 ± 112.30317.0 ± 117.34
TFPI, Change at Day 57383.3 ± 137.17140.0 ± 126.96460.5 ± 247.37371.0 ± 178.73377.2 ± 152.03
TFPI, Change at Day 85396.7 ± 216.54246.7 ± 51.81492.2 ± 308.46425.0 ± 266.57409.8 ± 230.80
TFPI, Change at Day 11330.0 ± 72.3041.5 ± 28.9939.0 ± 16.15-14.0 ± 33.179.7 ± 59.94
SecondaryChange From Baseline in Thrombin Generation (TGA) Lag Time

An ex vivo pharmacodynamic measure of thrombin generation (initiation of thrombin generation), the lag time is the time needed to form the first traces of thrombin.

Time frame:
Baseline, Study Day 2, 4, 8, 15, 22, 29, 30, 33, 57, 85 and 113
Reported as:
Mean · minutes
Change From Baseline in Thrombin Generation (TGA) Lag Time
minutesPF-06741086 300 mg SC QW Non-InhibitorPF-06741086 300 mg SC Loading + 150 mg SC QW Non-InhibitorPF-06741086 450 mg SC QW Non-InhibitorPF-06741086 300 mg SC QW InhibitorOverall PF-06741086 300 mg SC
TGA lag time, Change at Day 2-7.16 ± 5.865-2.77 ± 1.517-3.93 ± 1.919-4.13 ± 1.238-5.64 ± 4.365
TGA lag time, Change at Day 4-6.80 ± 6.079-2.80 ± 1.399-3.48 ± 1.957-4.17 ± 1.501-5.49 ± 4.467
TGA lag time, Change at Day 8-6.94 ± 5.882-2.88 ± 1.292-3.57 ± 2.018-4.43 ± 1.506-5.69 ± 4.327
TGA lag time, Change at Day 15-6.90 ± 5.897-3.07 ± 1.221-3.27 ± 1.870-4.29 ± 1.342-5.59 ± 4.327
TGA lag time, Change at Day 22-6.94 ± 5.978-2.80 ± 1.585-3.12 ± 2.097-4.34 ± 1.638-5.64 ± 4.422
TGA lag time, Change at Day 29-5.33 ± 4.871-2.77 ± 1.392-3.43 ± 2.016-4.32 ± 1.781-4.83 ± 3.537
TGA lag time, Change at Day 30-5.22 ± 4.893-2.77 ± 1.372-3.50 ± 2.082-4.48 ± 1.681-4.88 ± 3.640
TGA lag time, Change at Day 33-5.08 ± 4.414-2.40 ± 1.568-3.35 ± 2.261-4.52 ± 1.771-4.83 ± 3.329
TGA lag time, Change at Day 57-4.73 ± 4.711-2.28 ± 2.020-3.42 ± 1.962-3.78 ± 1.376-4.26 ± 3.346
TGA lag time,Change at Day 85-6.34 ± 5.745-3.10 ± 1.344-3.27 ± 2.014-3.33 ± 1.755-4.95 ± 4.497
TGA lag time, Change at Day 113-0.79 ± 7.4280.80 ± 0.2831.53 ± 5.3060.78 ± 5.251-0.06 ± 6.304
SecondaryChange From Baseline in Thrombin Generation (TGA) Peak

An ex vivo pharmacodynamic measure of thrombin generation (initiation of thrombin generation). The peak represents the highest thrombin concentration that can be generated. There may be patients who reach the peak faster or slower than others and this may represent hyper- or hypocoagulability, respectively.

Time frame:
Baseline, Study Day 2, 4, 8, 15, 22, 29, 30, 33, 57, 85 and 113
Reported as:
Mean · nanomole
Change From Baseline in Thrombin Generation (TGA) Peak
nanomolePF-06741086 300 mg SC QW Non-InhibitorPF-06741086 300 mg SC Loading + 150 mg SC QW Non-InhibitorPF-06741086 450 mg SC QW Non-InhibitorPF-06741086 300 mg SC QW InhibitorOverall PF-06741086 300 mg SC
TGA peak, Change at Day 272.93 ± 35.73470.92 ± 23.72168.18 ± 15.69363.41 ± 9.74368.17 ± 25.642
TGA peak, Change at Day 460.00 ± 30.19659.28 ± 30.15650.87 ± 20.68751.79 ± 14.92955.89 ± 23.278
TGA peak, Change at Day 849.36 ± 32.03356.00 ± 33.63650.30 ± 14.01954.36 ± 15.00751.86 ± 24.171
TGA peak, Change at Day 1549.01 ± 23.47152.57 ± 28.44046.40 ± 22.98540.90 ± 7.88644.96 ± 17.340
TGA peak, Change at Day 2244.50 ± 27.26052.07 ± 33.55838.15 ± 16.31344.41 ± 22.56744.46 ± 24.042
TGA peak, Change at Day 2942.95 ± 24.02649.72 ± 29.31638.23 ± 21.80842.48 ± 23.05742.72 ± 22.452
TGA peak, Change at Day 3035.93 ± 26.17751.75 ± 29.27637.72 ± 24.13648.62 ± 21.42741.70 ± 23.878
TGA peak, Change at Day 3376.68 ± 69.88746.83 ± 37.08436.25 ± 21.95554.10 ± 28.27666.42 ± 53.861
TGA peak, Change at Day 5737.13 ± 21.86632.57 ± 20.36834.67 ± 20.58433.93 ± 7.68835.53 ± 15.716
TGA peak, Change at Day 8537.60 ± 21.14269.92 ± 40.25030.15 ± 18.61430.15 ± 22.74334.16 ± 21.306
TGA peak, Change at Day 11324.37 ± 33.70316.05 ± 36.55743.33 ± 68.7946.93 ± 15.33416.32 ± 27.345
SecondaryChange From Baseline in Endogenous Thrombin Generation (TGA) Potential

An ex vivo pharmacodynamic measure of thrombin generation. The endogenous TGA potential represents the total amount of active thrombin formed during thrombin generation and the peak height the maximal amount of thrombin formed.

Time frame:
Baseline, Study Day 2, 4, 8, 15, 22, 29, 30, 33, 57, 85 and 113
Reported as:
Mean · nanomole*minute
Change From Baseline in Endogenous Thrombin Generation (TGA) Potential
nanomole*minutePF-06741086 300 mg SC QW Non-InhibitorPF-06741086 300 mg SC Loading + 150 mg SC QW Non-InhibitorPF-06741086 450 mg SC QW Non-InhibitorPF-06741086 300 mg SC QW InhibitorOverall PF-06741086 300 mg SC
Endogenous TGA Potential, Change at Day 2864.0 ± 250.60816.8 ± 211.13999.8 ± 249.591065.3 ± 161.71964.6 ± 227.95
Endogenous TGA Potential, Change at Day 4766.7 ± 236.94714.8 ± 275.75808.7 ± 288.78825.1 ± 294.44795.9 ± 258.54
Endogenous TGA Potential, Change at Day 8691.9 ± 301.43659.8 ± 295.11796.5 ± 151.00918.6 ± 276.26805.2 ± 301.66
Endogenous TGA Potential, Change at Day 15674.9 ± 244.61608.5 ± 242.81800.8 ± 334.99639.3 ± 145.74657.1 ± 194.32
Endogenous TGA Potential, Change at Day 22646.9 ± 295.05589.0 ± 274.33647.0 ± 236.38731.4 ± 302.89689.1 ± 290.60
Endogenous TGA Potential, Change at Day 29588.2 ± 239.00623.0 ± 188.84618.3 ± 276.51660.5 ± 340.36624.3 ± 282.93
Endogenous TGA Potential, Change at Day 30494.8 ± 247.86672.0 ± 226.25603.3 ± 332.44710.2 ± 272.54592.7 ± 270.33
Endogenous TGA Potential, Change at Day 33716.5 ± 391.60606.0 ± 280.39583.7 ± 291.25848.8 ± 387.17776.6 ± 376.05
Endogenous TGA Potential, Change at Day 57586.8 ± 200.04445.2 ± 220.86564.5 ± 287.43579.7 ± 147.04583.3 ± 167.42
Endogenous TGA Potential, Change at Day 85566.6 ± 202.22812.2 ± 198.80526.7 ± 297.03493.7 ± 368.68532.9 ± 280.20
Endogenous TGA Potential, Change at Day 113256.4 ± 347.9150.5 ± 290.62306.5 ± 440.04142.3 ± 361.25203.8 ± 344.10
SecondaryChange From Baseline in Prothrombin Fragments 1 + 2

An in vivo pharmacodynamic measure of thrombin generation (prothrombin cleavage). Prothrombin fragment 1+2 (F 1+2) is the amino terminus fragment of the prothrombin molecule. It is a polypeptide with a half-life of approximately 90 minutes. F 1+2 is released from prothrombin when prothrombin is converted to thrombin by the prothrombinase complex.

Time frame:
Baseline, Study Day 2, 4, 8, 15, 22, 29, 30, 33, 57, 85 and 113
Reported as:
Mean · picomole/liter
Change From Baseline in Prothrombin Fragments 1 + 2
picomole/literPF-06741086 300 mg SC QW Non-InhibitorPF-06741086 300 mg SC Loading + 150 mg SC QW Non-InhibitorPF-06741086 450 mg SC QW Non-InhibitorPF-06741086 300 mg SC QW InhibitorOverall PF-06741086 300 mg SC
Prothrombin fragments 1 + 2, Change at Day 2430.0 ± 383.03498.3 ± 484.40275.7 ± 206.71438.9 ± 507.68434.4 ± 432.08
Prothrombin fragments 1 + 2, Change at Day 4548.1 ± 455.671096.7 ± 1403.57574.5 ± 363.37730.3 ± 537.21639.2 ± 487.82
Prothrombin fragments 1 + 2, Change at Day 8450.3 ± 396.09562.2 ± 605.07413.0 ± 171.50580.7 ± 259.63515.5 ± 328.78
Prothrombin fragments 1 + 2, Change at Day 15481.7 ± 330.26349.7 ± 212.59389.2 ± 228.56571.1 ± 474.23526.4 ± 395.34
Prothrombin fragments 1 + 2, Change at Day 22608.1 ± 336.97322.3 ± 161.76420.2 ± 166.66524.1 ± 577.08566.1 ± 456.08
Prothrombin fragments 1 + 2, Change at Day 29650.3 ± 415.58288.0 ± 259.19577.7 ± 302.76429.3 ± 257.91531.3 ± 344.06
Prothrombin fragments 1 + 2, Change at Day 30655.7 ± 496.35486.0 ± 608.26521.0 ± 165.25580.8 ± 507.83618.3 ± 480.35
Prothrombin fragments 1 + 2, Change at Day 33761.3 ± 509.02642.5 ± 759.021527.7 ± 2499.96609.2 ± 380.74685.3 ± 435.87
Prothrombin fragments 1 + 2, Change at Day 57586.5 ± 473.53216.5 ± 173.44465.3 ± 300.84463.5 ± 397.57525.0 ± 421.78
Prothrombin fragments 1 + 2, Change at Day 85588.3 ± 483.80378.2 ± 207.16470.2 ± 244.21362.2 ± 378.54483.9 ± 436.47
Prothrombin fragments 1 + 2, Change at Day 113-6.6 ± 151.8716.5 ± 19.09-75.5 ± 76.86-58.2 ± 121.15-30.4 ± 135.52
SecondaryChange From Baseline in D-Dimer

An in vivo pharmacodynamic measure of thrombin generation (fibrin degradation). D-dimer is a fibrin degradation product, a small protein fragment present in the blood after a blood clot is degraded by fibrinolysis. D-dimer is one of the protein fragments produced when a blood clot gets dissolved in the body. It is normally undetectable or detectable at a very low level unless the body is forming and breaking down blood clots. Then, its level in the blood can significantly rise.

Time frame:
Baseline, Study Day 2, 4, 8, 15, 22, 29, 30, 33, 57, 85 and 113
Reported as:
Mean · microgram/milliliter
Change From Baseline in D-Dimer
microgram/milliliterPF-06741086 300 mg SC QW Non-InhibitorPF-06741086 300 mg SC Loading + 150 mg SC QW Non-InhibitorPF-06741086 450 mg SC QW Non-InhibitorPF-06741086 300 mg SC QW InhibitorOverall PF-06741086 300 mg SC
D-dimer, Change at Day 20.0393 ± 0.163030.0792 ± 0.222380.1900 ± 0.093010.1086 ± 0.305360.0739 ± 0.23790
D-dimer, Change at Day 40.2050 ± 0.244910.2842 ± 0.368960.3217 ± 0.232480.6729 ± 0.625240.4389 ± 0.51676
D-dimer, Change at Day 80.0743 ± 0.261110.2017 ± 0.297530.3292 ± 0.406350.5614 ± 0.549010.3179 ± 0.48422
D-dimer, Change at Day 150.0979 ± 0.256660.1942 ± 0.287480.2500 ± 0.234240.1900 ± 0.823100.1439 ± 0.58769
D-dimer, Change at Day 220.1364 ± 0.278020.2167 ± 0.338770.2000 ± 0.261090.1829 ± 1.278020.1596 ± 0.88887
D-dimer, Change at Day 290.0633 ± 0.200290.2308 ± 0.323550.1517 ± 0.42347-0.0129 ± 1.174910.0223 ± 0.84172
D-dimer, Change at Day 300.1350 ± 0.323880.1492 ± 0.263450.2133 ± 0.33914-0.0833 ± 1.315490.0258 ± 0.92048
D-dimer, Change at Day 330.0800 ± 0.287960.1283 ± 0.375190.1233 ± 0.49855-0.1700 ± 1.68635-0.0450 ± 1.16076
D-dimer, Change at Day 570.1942 ± 0.300490.2175 ± 0.225540.1233 ± 0.361220.4033 ± 0.371200.2988 ± 0.34001
D-dimer, Change at Day 850.1664 ± 0.305210.5860 ± 1.000030.1833 ± 0.438400.2300 ± 0.603950.1958 ± 0.44682
D-dimer, Change at Day 113-0.1000 ± 0.221270.1875 ± 0.265170.0175 ± 0.41838-0.7833 ± 1.60090-0.4154 ± 1.10366
SecondaryChange From Baseline in Dilute Prothrombin Time

An ex vivo pharmacodynamic measure of thrombin generation (via extrinsic pathway). Clotting time is measured using a dilute prothrombin time reagent consisting of a unique formulation of relipidated recombinant tissue factor and calcium.

Time frame:
Baseline, Study Day 2, 4, 8, 15, 22, 29, 30, 33, 57, 85 and 113
Reported as:
Mean · seconds
Change From Baseline in Dilute Prothrombin Time
secondsPF-06741086 300 mg SC QW Non-InhibitorPF-06741086 300 mg SC Loading + 150 mg SC QW Non-InhibitorPF-06741086 450 mg SC QW Non-InhibitorPF-06741086 300 mg SC QW InhibitorOverall PF-06741086 300 mg SC
Dilute prothrombin Time, Change at Day 2-27.84 ± 21.023-13.32 ± 25.780-31.25 ± 13.606-17.14 ± 26.167-22.49 ± 23.470
Dilute prothrombin Time, Change at Day 4-30.03 ± 24.312-17.87 ± 20.042-34.50 ± 18.306-14.70 ± 30.971-22.36 ± 27.907
Dilute prothrombin Time, Change at Day 8-23.63 ± 19.991-15.10 ± 22.129-31.23 ± 19.645-20.97 ± 33.969-22.30 ± 26.813
Dilute prothrombin Time, Change at Day 15-20.73 ± 23.070-19.33 ± 20.853-33.53 ± 14.8801.11 ± 27.208-9.81 ± 26.753
Dilute prothrombin Time, Change at Day 22-21.40 ± 22.351-10.55 ± 16.057-26.78 ± 32.501-21.61 ± 30.842-21.51 ± 25.877
Dilute prothrombin Time, Change at Day 29-15.32 ± 13.867-7.10 ± 20.643-40.40 ± 22.458-18.03 ± 24.600-16.78 ± 19.613
Dilute prothrombin Time, Change at Day 30-13.27 ± 13.399-23.45 ± 19.413-45.18 ± 21.372-17.47 ± 25.729-15.37 ± 19.680
Dilute prothrombin Time, Change at Day 33-23.35 ± 17.690-21.23 ± 20.010-29.10 ± 20.783-19.97 ± 19.297-21.66 ± 17.737
Dilute prothrombin Time, Change at Day 57-14.75 ± 14.393-12.03 ± 30.806-26.80 ± 12.911-11.72 ± 42.872-13.23 ± 30.531
Dilute prothrombin TIme, Change at Day 85-20.99 ± 25.424-25.80 ± 24.334-23.43 ± 26.166-12.42 ± 34.871-17.03 ± 29.148
Dilute prothrombin Time, Change at Day 113-16.44 ± 13.57814.30 ± 61.235-39.63 ± 20.182-12.78 ± 28.226-14.75 ± 20.682
SecondaryNumber of Participants Who Tested Positive for Anti-PF-06741086 Antibody (ADA)

Human plasma ADA samples were analyzed for the detection of anti PF-06741086 antibodies by using semi-quantitative electrochemiluminescence (ECL) method. The criterion for positive result of ADA samples was ADA titer \>=1.53. Treatment induced are negative prior to dosing and become positive during/after dosing. Treatment boosted are positive prior to dosing but titer increases during/after dosing.

Time frame:
Baseline up to Study Day 113
Reported as:
Count of participants · Participants
Number of Participants Who Tested Positive for Anti-PF-06741086 Antibody (ADA)
ParticipantsPF-06741086 300 mg SC QW Non-InhibitorPF-06741086 300 mg SC Loading + 150 mg SC QW Non-InhibitorPF-06741086 450 mg SC QW Non-InhibitorPF-06741086 300 mg SC QW InhibitorOverall PF-06741086 300 mg SCTotal
ADA incidence012003
Participants with treatment induced ADA incidence012003
Participants with treatment boosted ADA incidence000000
SecondaryNumber of Participants Who Tested Positive for Neutralizing Antibody (NAb)

Human plasma NAb samples were analyzed for the presence or absence of NAb to PF-06741086 using semi-quantitative electrochemiluminescence (ECL) method. Treatment induced are negative prior to dosing and become positive during/after dosing. Treatment boosted are positive prior to dosing but titer increases during/after dosing.

Time frame:
Baseline up to Study Day 113
Reported as:
Count of participants · Participants
Number of Participants Who Tested Positive for Neutralizing Antibody (NAb)
ParticipantsPF-06741086 300 mg SC QW Non-InhibitorPF-06741086 300 mg SC Loading + 150 mg SC QW Non-InhibitorPF-06741086 450 mg SC QW Non-InhibitorPF-06741086 300 mg SC QW InhibitorOverall PF-06741086 300 mg SCTotal
NAb incidence000000
Participants with treatment induced NAb incidence000000
Participants with treatment boosted NAb incidence000000

Adverse events

Collected over 113 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PF-06741086 300 mg SC QW Non-Inhibitor0/7 (0%)1/7 (14.3%)6/7 (85.7%)
PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor0/6 (0%)1/6 (16.7%)4/6 (66.7%)
PF-06741086 450 mg SC QW Non-Inhibitor0/6 (0%)1/6 (16.7%)6/6 (100%)
PF-06741086 300 mg SC QW Inhibitor0/7 (0%)1/7 (14.3%)4/7 (57.1%)
Overall PF-06741086 300 mg SC0/14 (0%)2/14 (14.3%)10/14 (71.4%)
Total0/26 (0%)4/26 (15.4%)20/26 (76.9%)
Most frequent serious events
Most frequent serious events
EventPF-06741086 300 mg SC QW Non-InhibitorPF-06741086 300 mg SC Loading + 150 mg SC QW Non-InhibitorPF-06741086 450 mg SC QW Non-InhibitorPF-06741086 300 mg SC QW InhibitorOverall PF-06741086 300 mg SCTotal
CholelithiasisHepatobiliary disorders0/70/61/60/70/141/26
Physical assaultSocial circumstances0/71/60/60/70/141/26
Tooth socket haemorrhageGastrointestinal disorders0/70/60/61/71/141/26
AppendicitisInfections and infestations1/70/60/60/71/141/26
Most frequent other events
Showing 10 of 36
Most frequent other events
EventPF-06741086 300 mg SC QW Non-InhibitorPF-06741086 300 mg SC Loading + 150 mg SC QW Non-InhibitorPF-06741086 450 mg SC QW Non-InhibitorPF-06741086 300 mg SC QW InhibitorOverall PF-06741086 300 mg SCTotal
Injection site swellingGeneral disorders0/70/62/61/71/143/26
HeadacheNervous system disorders0/70/62/60/70/142/26
HypertensionVascular disorders0/72/61/60/70/143/26
Injection site bruisingGeneral disorders2/70/60/60/72/142/26
Abdominal painGastrointestinal disorders0/70/61/60/70/141/26
Gastrooesophageal reflux diseaseGastrointestinal disorders0/71/60/60/70/141/26
FatigueGeneral disorders1/70/61/60/71/142/26
Injection site indurationGeneral disorders1/70/61/60/71/142/26
Injection site painGeneral disorders1/71/61/60/71/143/26
Injection site warmthGeneral disorders0/70/61/60/70/141/26

Baseline characteristics

Baseline analysis population included all participants who received at least 1 dose of study treatment.

Age, Categorical
Age, Categorical(Participants)PF-06741086 300 mg SC QW Non-InhibitorPF-06741086 300 mg SC Loading + 150 mg SC QW Non-InhibitorPF-06741086 450 mg SC QW Non-InhibitorPF-06741086 300 mg SC QW InhibitorTotal
<=18 years00000
Between 18 and 65 years766726
>=65 years00000
Age, Continuous
Age, Continuous(Years)PF-06741086 300 mg SC QW Non-InhibitorPF-06741086 300 mg SC Loading + 150 mg SC QW Non-InhibitorPF-06741086 450 mg SC QW Non-InhibitorPF-06741086 300 mg SC QW InhibitorTotal
Mean31.9 ± 8.1728.7 ± 8.3141.7 ± 15.8744.1 ± 9.4436.7 ± 12.05
Sex: Female, Male
Sex: Female, Male(Participants)PF-06741086 300 mg SC QW Non-InhibitorPF-06741086 300 mg SC Loading + 150 mg SC QW Non-InhibitorPF-06741086 450 mg SC QW Non-InhibitorPF-06741086 300 mg SC QW InhibitorTotal
Female00000
Male766726
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PF-06741086 300 mg SC QW Non-InhibitorPF-06741086 300 mg SC Loading + 150 mg SC QW Non-InhibitorPF-06741086 450 mg SC QW Non-InhibitorPF-06741086 300 mg SC QW InhibitorTotal
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American440412
White326314
More than one race00000
Unknown or Not Reported00000
08

Study locations

10 sites
  • UC Denver Hemophilia and Thrombosis Center - Pharmacy
    Aurora, Colorado 80045, United States
  • UC Denver Hemophilia and Thrombosis Center
    Aurora, Colorado 80045, United States
  • Pharmacy
    Chicago, Illinois 60612, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Hospital Dr. Sotero del Rio
    Santiago, 8207257, Chile
  • Klinicki bolnicki centar Zagreb
    Zagreb, 10000, Croatia
  • Klinika Hematologii i Transplantologii Uniwersyteckie Centrum Kliniczne
    Gdansk, 80-952, Poland
  • Phoenix Pharma (Pty) Ltd
    Port Elizabeth, Eastern CAPE 6001, South Africa
  • Haemophilia Comprehensive Care Centre
    Johannesburg, Gauteng 2193, South Africa
  • UniversitatsSpital Zurich, Klinik fur Hamatologie
    Zurich, 8091, Switzerland
09

References and documents

Publications

  • Mahlangu JN, Lamas JL, Morales JC, Malan DR, Salek SZ, Wang M, Boggio LN, Hegemann I, Mital A, Cardinal M, Zhu T, Sun P, Arkin S. A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia. Br J Haematol. 2023 Jan;200(2):229-239. doi: 10.1111/bjh.18420. Epub 2022 Aug 23. PubMed 35999026 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in Dec 2018, 20 months.

Results were first posted in Dec 2019, 1 year after primary completion.

Of 18 phase 2 interventional studies under Hemophilia A, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 20. This study's 20 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2016
First posted
Nov 29, 2016
StartActual
Mar 8, 2017
Primary completionActual
Dec 3, 2018
CompletionActual
Dec 3, 2018
Results first posted
Dec 4, 2019
Last update
Dec 4, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02974855
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 29, 2016
Start date
Mar 8, 2017
Primary completion
Dec 3, 2018
Completion
Dec 3, 2018
Results posted
Dec 4, 2019
Last update
Dec 4, 2019

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Marstacimab

Start the discussion